PDGFR x c-Kit x VEGFR2 x FLT3 x Syk x PKC

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML).
The names of the study drugs involved in this study are:
Revumenib (SNDX-5613) (a type of menin inhibitor)
Midostaurin (a type of multi-kinase including FLT3 inhibitor)
Cytarabine (a type of antineoplastic agent)
Daunorubicin (a type of antineoplastic agent)